{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:36:33Z","timestamp":1787747793406,"version":"build-2784847793"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7186-26","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:10:46Z","timestamp":1778883046000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa"],"prefix":"10.2169","author":[{"given":"Kengo","family":"Asada","sequence":"first","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyu","family":"Tomiki","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamashiro","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimei","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet 398: 143-155, 2021.","DOI":"10.1016\/S0140-6736(21)01324-6"},{"key":"2","unstructured":"2. Chiang C-H, Jaroenlapnopparat A, Colak SC, et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology S0016-5085(25)00845-5, 2025."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine 393: 2409-2420, 2025.","DOI":"10.1056\/NEJMoa2505928"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jones LA, Brierley DI. GLP-1 and the Neurobiology of Eating Control: Recent Advances. Endocrinology 166: bqae167, 2025.","DOI":"10.1210\/endocr\/bqae167"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Edholm T, Degerblad M, Gryb\u00e4ck P, et al. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil 22: 1191-1200, e315, 2010.","DOI":"10.1111\/j.1365-2982.2010.01554.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Javed F, Shaat IAA, Oyibo SO. Semaglutide-Induced Small Bowel Pseudo-Obstruction and Ileitis in a Patient With Type 2 Diabetes: A Case Report. Cureus 17: e88350, 2025.","DOI":"10.7759\/cureus.88350"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nagib N, Avila D, Partyka J, Kamyab A. Weighing the Risks: Small Bowel Obstruction Associated With Semaglutide Use in the Postoperative Abdomen. Cureus 17: e88589, 2025.","DOI":"10.7759\/cureus.88589"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gandhi A, Khanam V, Peterson D, Patel F, Kulairi Z. MON-681 Dulaglutide Commonly Known as Trulicity; An Anti-Diabetic Medication Causing Small Bowel Obstruction. J Endocr Soc 4: MON-681, 2020.","DOI":"10.1210\/jendso\/bvaa046.609"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA 330: 1795-1797, 2023.","DOI":"10.1001\/jama.2023.19574"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nafisah SB, Almatrafi D, Al-Mulhim K. Liraglutide overdose: A case report and an updated review. Turk J Emerg Med 20: 46-49, 2020.","DOI":"10.4103\/2452-2473.276386"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Diec CB, Cook EA, Nguyen NT. Asymptomatic Subcutaneous Semaglutide Overdose: A Case Report and Literature Review. Journal of Pharmacy Practice 08971900251335111, 2025.","DOI":"10.1177\/08971900251335111"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mathew A, Hannoodee H. FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report. J Endocr Soc 7: bvad114.862, 2023.","DOI":"10.1210\/jendso\/bvad114.862"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lorenz N, Stauffer J, Abouafech A, Mourad A, Bray K. Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report. Cureus 17: e90657, 2025.","DOI":"10.7759\/cureus.90657"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Maruna P, Frasko R, G\u00fcrlich R. Plasma procalcitonin in patients with ileus. Relations to other inflammatory parameters. Physiol Res 57: 481-486, 2008.","DOI":"10.33549\/physiolres.931249"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315: 801-810, 2016.","DOI":"10.1001\/jama.2016.0287"},{"key":"16","first-page":"5967","volume":"37","author":"M Ishizuka","year":"2017","unstructured":"16. Ishizuka M, Shibuya N, Nagata H, et al. Perioperative Administration of Traditional Japanese Herbal Medicine Daikenchuto Relieves Postoperative Ileus in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis. Anticancer Research 37: 5967-5974, 2017.","journal-title":"Anticancer Research","ISSN":"https:\/\/id.crossref.org\/issn\/0250-7005","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wade TD. Recent Research on Bulimia Nervosa. Psychiatr Clin North Am 42: 21-32, 2019.","DOI":"10.1016\/j.psc.2018.10.002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Crone C, Fochtmann LJ, Attia E, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders. Am J Psychiatry 180: 167-171, 2023.","DOI":"10.1176\/appi.ajp.23180001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Naess\u00e9n S, Carlstr\u00f6m K, Holst JJ, Hellstr\u00f6m PM, Hirschberg AL. Women with bulimia nervosa exhibit attenuated secretion of glucagon-like peptide 1, pancreatic polypeptide, and insulin in response to a meal. Am J Clin Nutr 94: 967-972, 2011.","DOI":"10.3945\/ajcn.111.014837"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Keel PK, Bodell LP, Appelbaum J, Williams DL. Test of a biobehavioral model linking weight suppression to binge-eating severity via leptin and glucagon-like peptide 1 in bulimia nervosa and related syndromes in women. Psychol Med 55: e177, 2025.","DOI":"10.1017\/S0033291725100871"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Balantekin KN, Kretz MJ, Mietlicki-Baase EG. The emerging role of glucagon-like peptide 1 in binge eating. J Endocrinol 262: e230405, 2024.","DOI":"10.1530\/JOE-23-0405"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. McElroy SL, Mori N, Guerdjikova AI, Keck PE. Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. Med Hypotheses 111: 90-93, 2018.","DOI":"10.1016\/j.mehy.2017.12.029"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Xu Y, Amdanee N, Zhang X. Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment. CNS Drugs 35: 1265-1274, 2021.","DOI":"10.1007\/s40263-021-00859-0"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lin J, Wei S, Peng Y, et al. Gastrointestinal adverse events associated with SNRIs: A FAERS-based pharmacovigilance study. J Affect Disord 387: 119484, 2025.","DOI":"10.1016\/j.jad.2025.119484"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wang Z, Li H, Kang Y, Liu Y, Shan L, Wang F. Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis. Ther Clin Risk Manag 18: 799-812, 2022.","DOI":"10.2147\/TCRM.S363404"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Kamal N, Chami T, Andersen A, Rosell FA, Schuster MM, Whitehead WE. Delayed gastrointestinal transit times in anorexia nervosa and bulimia nervosa. Gastroenterology 101: 1320-1324, 1991.","DOI":"10.1016\/0016-5085(91)90083-W"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240-1250, 2008.","DOI":"10.1016\/S0140-6736(08)61206-4"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans. Diabetes 60: 1561-1565, 2011.","DOI":"10.2337\/db10-0474"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Eldor R, Avraham N, Rosenberg O, et al. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen. Diabetes Care 48: 1607-1611, 2025.","DOI":"10.2337\/dc25-0690"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7186-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:27:19Z","timestamp":1778902039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7186-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":29,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7186-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7186-26"}}